2. Academic Validation
  3. Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis

  • Acta Biochim Biophys Sin (Shanghai). 2024 Apr 25;56(4):621-633. doi: 10.3724/abbs.2024025.
Peiguang Zhang 1,  Jieqiong Cao 1,  Xujing Liang 2,  Zijian Su 1,  Bihui Zhang 1,  Zhenyu Wang 1,  Junye Xie 1,  Gengrui Chen 3,  Xue Chen 1,  Jinting Zhang 1,  Yanxian Feng 3,  Qin Xu 4,  Jianping Song 4,  An Hong 1,  Xiaojia Chen 1,  Yibo Zhang 1
Affiliations

Affiliations

  • 1 Department of Cell Biology, College of Life Science and Technology, Jinan University; State Key Laboratory of Bioactive Molecules and Druggability Assessment, Jinan University; National Engineering Research Center of Genetic Medicine; Guangdong Provincial Key Laboratory of Bioengineering Medicine; Guangdong Provincial Biotechnology Drug & Engineering Technology Research Center, Jinan University, Guangzhou 510632, China.
  • 2 Department of Infectious Disease, the First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
  • 3 School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.
  • 4 Guangzhou University of Traditional Chinese Medicine, Guangzhou 510006, China.
PMID: 38516704 DOI: 10.3724/abbs.2024025
Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, with a global prevalence of 25%. Patients with NAFLD are more likely to suffer from advanced liver disease, Cardiovascular Disease, or type II diabetes. However, unfortunately, there is still a shortage of FDA-approved therapeutic agents for NAFLD. Lian-Mei-Yin (LMY) is a traditional Chinese medicine formula used for decades to treat liver disorders. It has recently been applied to type II diabetes which is closely related to Insulin resistance. Given that NAFLD is another disease involved in Insulin resistance, we hypothesize that LMY might be a promising formula for NAFLD therapy. Herein, we verify that the LMY formula effectively reduces hepatic steatosis in diet-induced zebrafish and NAFLD model mice in a time- and dose-dependent manner. Mechanistically, LMY suppresses Yap1-mediated Foxm1 activation, which is crucial for the occurrence and development of NAFLD. Consequently, lipogenesis is ameliorated by LMY administration. In summary, the LMY formula alleviates diet-induced NAFLD in zebrafish and mice by inhibiting Yap1/Foxm1 signaling-mediated NAFLD pathology.

Keywords

Foxm1; Lian-Mei-Yin; Yap1; non-alcoholic fatty liver disease; traditional Chinese medicine.

Figures
Products